Skip to content
Company Analysis

VolitionRX Limited VNRX

A comprehensive view of key metrics, scores, and financial health for VolitionRX Limited

Overview of VolitionRx Limited

VNRX ASE
Healthcare Medical Devices Framework: Medical Devices & Diagnostics Micro Cap
VolitionRx Limited (VNRX), is a Micro Cap company, in the Medical Devices industry, last closed at $0.21, about 0.0% overvalued vs fair value, -97.4% 1Y return, ranked 1076/1145 in sector.
Metrics Rev Growth 40.0% ROE 79.0%
USD 0.21
5.00%
(Delayed)
• Vol 90d: 109.7%
52-Week Range
Market Cap
$2.70M
Enterprise Value
$9.25M
Overall Score
View breakdown
Overall
Growth
Weak
Profitability
Weak
Health
Weak
Efficiency
Weak
Valuation
Fair
Growth
Weak
Profitability
Weak
Health
Weak
Efficiency
Weak
Valuation
Fair
Completeness: 82%
Confidence: 90%
Updated: Oct 31
Top Beats

Quick Facts

Website https://volition.com
HQ Henderson, NV
Employees 75
Fiscal year Dec 31

Next Events

Earnings Nov 12 Estimated

Fair Value Snapshot

Bear Base Bull
$-2
$-2
$-2
Current: $0.21

Engine Room Money Flow™

Micro Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$1.7M
40%%
Gross Profit
$1.2M
59.1%%
Operating Income (GAAP)
-$21.7M
19.6%%
EBITDA
-$19.8M
22.6%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
71.4%
Excellent

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
2
Active Leaks
1/2
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating VolitionRX Limited's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
60
/100
Moderate
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Elite Gross Margins Gross margin quality is top-tier vs peers (score 1.00). This signals strong consumable attach-rate economics.
  • Superior Capital Returns Capital return quality is top-tier (score 0.96). High ROIC indicates the business is reinvesting at attractive rates.

Key risks

  • Weak FCF Generation FCF margin quality lags peers (score 0.16). Below-peer FCF conversion is a MedTech quality warning.
  • Below-Peer Operating Margin Operating margin level is below peers (score 0.17). SG&A leverage needs improvement to close the gap.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Strong
100
Premium

Signals, strengths and risks for Pricing Power & Consumable Moat

Premium

Signals, strengths and risks for R&D Pipeline & Capital Returns

Premium

Signals, strengths and risks for FCF Quality & Cash Conversion

Premium

Signals, strengths and risks for Commercial Execution

Premium

Signals, strengths and risks for Capital Structure & Resilience

Premium

Signals, strengths and risks for Growth Durability

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 79% Coverage
Trade-Off Triangle Visualization A ternary plot showing VNRX's balance between Growth (48.7%), Profitability (34.2%), and Safety (17.1%). Growth 49% Safety 17% Profitability 34%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

68th percentile vs peers
69
Key Signals
Rev Growth YoY 40.0% 91p Revenue CAGR 3Y 78.0% 93p EPS Growth YoY 29.8% 55p TSR -70.3% 6p Asset Growth YoY -26.6% 11p
Strengths
  • Rev Growth YoY in top 20% of peers (40.0%, 91th percentile)
  • Revenue CAGR 3Y in top 20% of peers (78.0%, 93th percentile)
  • Gross Profit Margin in top 20% of peers (1.00, 98th percentile)
  • ROIC in top 20% of peers (91.8%, 96th percentile)
  • Growth above peer median with strong metric coverage (85%)
Risks

No significant risks identified for this axis.

Profitability

48th percentile vs peers
48
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

24th percentile vs peers
24
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for VolitionRX Limited.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$-2.14
- - -
- upside
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000